P
Peter Hohenberger
Researcher at Heidelberg University
Publications - 306
Citations - 23325
Peter Hohenberger is an academic researcher from Heidelberg University. The author has contributed to research in topics: GiST & Sarcoma. The author has an hindex of 63, co-authored 276 publications receiving 19017 citations. Previous affiliations of Peter Hohenberger include European Organisation for Research and Treatment of Cancer & University of Göttingen.
Papers
More filters
Journal ArticleDOI
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf,Jean-Yves Blay,Sant P. Chawla,Dong Wan Kim,B. Bui-Nguyen,Paolo G. Casali,Patrick Schöffski,Massimo Aglietta,Arthur P. Staddon,Yasuo Beppu,Axel Le Cesne,Hans Gelderblom,Ian Judson,Nobuhito Araki,M. Ouali,Sandrine Marreaud,Rachel Hodge,Mohammed R. Dewji,Corneel Coens,George D. Demetri,Christopher D.M. Fletcher,Angelo Paolo Dei Tos,Peter Hohenberger +22 more
TL;DR: This phase 3 study investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.
Journal ArticleDOI
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Paolo G. Casali,N. Abecassis,Sebastian Bauer,R. Biagini,Stefan S. Bielack,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Thomas Brodowicz,Javier Martin Broto,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,Palma Dileo,Mikael Eriksson,Alexander Fedenko,Virginia Ferraresi,Andrea Ferrari,Silvia Ferrari,A.M. Frezza,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,Rick L. Haas,A. Hannu,B. Hassan,Peter Hohenberger,Rolf D. Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Maria Abbondanza Pantaleo,R. Piana,Piero Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,K. Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,Jeremy Whelan,Eva Wardelmann,Olga Zaikova,Jean-Yves Blay +62 more
Journal ArticleDOI
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri,Peter Reichardt,Yoon-Koo Kang,Jean-Yves Blay,Piotr Rutkowski,Hans Gelderblom,Peter Hohenberger,Michael F. Leahy,Margaret von Mehren,Heikki Joensuu,Giuseppe Badalamenti,Martin E. Blackstein,Axel Le Cesne,Patrick Schöffski,Robert G. Maki,Sebastian Bauer,Binh Bui Nguyen,Jianming Xu,Toshirou Nishida,John Chung,Christian Kappeler,Iris Kuss,D. Laurent,Paolo G. Casali +23 more
TL;DR: The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on standard treatments.
Journal ArticleDOI
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson,Jaap Verweij,Hans Gelderblom,Jörg T. Hartmann,Jörg T. Hartmann,Patrick Schöffski,Jean-Yves Blay,J. Martijn Kerst,Josef Sufliarsky,Jeremy Whelan,Peter Hohenberger,Anders Krarup-Hansen,Thierry Alcindor,Thierry Alcindor,Sandrine Marreaud,Saskia Litière,Catherine Hermans,Cyril Fisher,Pancras C.W. Hogendoorn,A Paolo dei Tos,Winette T. A. van der Graaf +20 more
TL;DR: This phase 3 randomised controlled trial assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorbicin alone.
Journal ArticleDOI
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Heikki Joensuu,Mikael Eriksson,Kirsten Sundby Hall,Jörg T. Hartmann,Daniel Pink,Jochen Schütte,Giuliano Ramadori,Peter Hohenberger,Justus Duyster,Salah-Eddin Al-Batran,Marcus Schlemmer,Sebastian Bauer,Eva Wardelmann,Maarit Sarlomo-Rikala,Bengt Nilsson,Harri Sihto,Odd R. Monge,Petri Bono,Raija Kallio,Aki Vehtari,M. Leinonen,Thor Alvegård,Peter Reichardt +22 more
TL;DR: Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo and overall survival of GIST patients with a high risk of Gist recurrence.